MedTrace Logo

Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm

NCT05538767 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2023-06-15

No results posted yet for this study

Summary

To compare the efficacy and safety of emodepside to that of albendazole (Zentel®) in participants aged 12-60, inclusive, infected with hookworm.

Conditions

  • Hookworm Infections

Interventions

DRUG

Emodepside

Treatment with Emodepside 30 mg

DRUG

Albendazole 400mg

Treatment with Albendazole 400 mg

Sponsors & Collaborators

  • Public Health Laboratory Ivo de Carneri

    collaborator OTHER

  • Jennifer Keiser

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-16
Primary Completion
2023-04-11
Completion
2023-04-11

Countries

  • Tanzania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05538767 on ClinicalTrials.gov